Company profile
Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07280299 | phase2 | not_yet_recruiting | 2026-05-30 | 2028-06-30 | Gain Therapeutics, Inc. | Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease |
| NCT06732180 | phase1 | recruiting | 2025-02-21 | 2025-11-30 | Gain Therapeutics, Inc. | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease |
FDA applications (0)
No records yet.